

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobilis RT+IBmulti+G+ND emulsion for injection for chickens

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 0.5 ml dose contains:

Active substances:

Inactivated viral antigens of:

AMPV strain But1# 8544: inducing $\geq 9.5 \log_2$ ELISA units*

IBV strain M41(Massachusetts):inducing $\geq 5.5 \log_2$ VN units*

IBV strain 249g (D274/D207): inducing $\geq 4.0 \log_2$ VN units*

IBDV strain D78: inducing $\geq 14.5 \log_2$ VN units*

NDV strain Clone 30: inducing $\geq 4.0 \log_2$ HI units per 1/50th dose*
or containing ≥ 50 PD₅₀ units

* serological response in chickens

Adjuvant:

Liquid paraffin: 215 mg

Excipients:

Qualitative composition of excipients and other constituents
Polysorbate 80
Sorbitan mono-oleate
Glycine
Water for injections

White to nearly white oily emulsion.

3. CLINICAL INFORMATION

3.1 Target species

Chickens (future breeders).

3.2 Indications for use for each target species

Active immunisation of breeder chickens for:

- reduction of infection and prevention of egg drop caused by the Massachusetts serotype of infectious bronchitis virus (IBV);

- reduction of egg drop and eggshell defects caused by the D274/D207 serotype of infectious bronchitis virus (IBV);
- reduction of infection caused by Newcastle disease virus (NDV);
- prevention of respiratory signs and reduction of egg drop and eggshell defects related to avian metapneumovirus (AMPV);
- passive immunisation of the progeny of the vaccinated birds against infectious bursal disease virus (IBDV).

Onset of immunity:

- IBV, NDV, AMPV: 4 weeks post-vaccination
- IBDV in progeny: 1 day of age

Duration of immunity:

- IBV, NDV, AMPV: one laying period
- IBDV in progeny: 4 weeks

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Vaccination with inactivated vaccine will not completely prevent shedding of wild type virus after infection. Therefore, this vaccine is only meant to reduce the clinical signs and not as a tool for eradication of the diseases.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit.

Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Chickens (future breeders):

Very common (>1 animal / 10 animals treated):	Injection site swelling ¹
--	--------------------------------------

¹ A mild swelling which may be observed for 2 weeks.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Laying birds:

Do not use in birds in lay and within 4 weeks before the start of the laying period.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

The vaccine should be given to chickens around 14-20 weeks of age but not later than 4 weeks before the expected onset of lay.

If live vaccines were used to prime chickens against infectious bronchitis, rhinotracheitis, Newcastle disease and infectious bursal disease, the vaccine should be given at least 4 weeks after the administration of the live vaccines.

Administer one dose of 0.5 ml vaccine per chicken via intramuscular injection in the thigh or chest muscle.

Before using the vaccine allow it to reach ambient temperature (15 °C – 25 °C).

Shake the bottle vigorously before use and periodically during use.

Ensure that vaccination equipment is clean and sterile before use.

Do not use vaccination equipment with rubber parts as the excipient may damage certain types of rubber.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

After administration of a double dose the reactions are not different from those observed after a single dose.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Any person intending to manufacture, import, possess, distribute, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

3.12 Withdrawal periods

Zero days.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI01AA06.

The antigens are inactivated with formalin or β -propiolactone and suspended in the aqueous phase of a water-in-oil adjuvant emulsion, in order to enhance a prolonged stimulation of immunity.

The vaccine is intended to stimulate active immunity against avian metapneumovirus, against the Massachusetts and D274/D207 serotypes of infectious bronchitis virus and against Newcastle disease; and to stimulate active immunity against infectious bursal (Gumboro) disease to provide passive immunity to the progeny.

An enhanced immune response is obtained when the veterinary medicinal product is used for booster immunisation after priming the birds with live vaccines, if available, against infectious bronchitis, rhinotracheitis, Newcastle disease and infectious bursal disease. The best results will be obtained if vaccination with the inactivated vaccine takes place at least 4 weeks after administration of the live primer.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 3 hours.

5.3 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.

5.4 Nature and composition of immediate packaging

Bottle of polyethylene terephthalate (PET), closed with a nitril rubber stopper and sealed with a colour coded aluminium cap.

Pack sizes:

Cardboard box with one bottle of 250 ml (500 doses) or 500 ml (1000 doses).
Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Limited
Walton Manor
Walton
Milton Keynes
MK7 7AJ
United Kingdom

7. MARKETING AUTHORISATION NUMBER

Vm 01708/3023

8. DATE OF FIRST AUTHORISATION

27 April 2000

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

June 2024

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

Approved: 20 June 2024

Gavin Hall